Tech Company Financing Transactions

Kyverna Therapeutics Funding Round

On 8/3/2023, Kyverna Therapeutics secured $60 million in Series B funding from Bain Capital Life Sciences, CAM Capital and Gilead Sciences.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

740 Heinz Ave.
Berkeley, CA 94710
USA

Phone

Undisclosed

Website

www.kyvernatx.com

Email Address

[email protected]

Overview

We are a cell therapy company developing a new class of treatments and potential cures for serious autoimmune diseases. Autoimmune diseases result from a failure of the immune system to distinguish self from non-self, caused by autoreactive B cells and T cells attacking the body's own tissues.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Dominic Borie

        

Chief Scientific Officer

Jeffrey Greve

        

VP - General Counsel

Gregory Giotta

        

VP - Operations

Ryan Jones

        

Browse more venture capital transactions:

Prev: 8/3/2023: CoreWeave venture capital transaction
Next: 8/4/2023: Genomika venture capital transaction

Share this article

About Our Venture Capital Transactions Database

Our team works diligently to document every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary